GlassScriptPhysician profile
Jessica E Narrett
NPI 1053832790
$3,415.85
in general payments reported to CMS, 2019-2025
28 companies · $433 in 2025
The $433 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $583 · 2022: $688 · 2023: $662 · 2024: $1,050 · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,145.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $918.51 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $532.42 | 2021-2025 | Mounjaro, Trulicity, Zepbound |
| Astrazeneca Pharmaceuticals LP | $440.02 | 2021-2025 | Airsupra, Farxiga, Fasenra |
| Abbvie INC. | $350.56 | 2021-2025 | |
| Pfizer INC. | $144.05 | 2021-2024 | |
| Astellas Pharma US INC | $96.52 | 2025 | Veozah |
| Glaxosmithkline, LLC. | $95.92 | 2022-2025 | Trelegy Ellipta |
| Mylan Specialty L.P. | $84.03 | 2021 | |
| Axsome Therapeutics, INC. | $78.03 | 2024 | Auvelity |
| Amgen INC. | $64.96 | 2023-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.92 | 2021-2024 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $60.23 | 2024-2025 | Caplyta |
| Exact Sciences Corporation | $59.39 | 2023-2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.69 | 2021 | |
| Amarin Pharma, INC. | $57.11 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $48.74 | 2024-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $30.61 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.51 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $26.45 | 2021 | |
| Janssen Pharmaceuticals, INC | $26.26 | 2022 | |
| Sanofi-Aventis U.S. LLC | $24.72 | 2021-2022 | |
| Abiomed | $23.49 | 2024 | |
| Vanda Pharmaceuticals INC. | $20.61 | 2021 | |
| Pulmonx Corporation | $19.11 | 2024 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Bausch Health US, LLC | $18.26 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $16.33 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.82 | 2023 | Trintellix |
| Medtronic, INC. | $15.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Narrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.